DVAX · As filed with the SEC
Dynavax Technologies balance sheet, by fiscal year
The statement as Dynavax Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD thousands
| USD thousands | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 95,883 | 150,279 | 202,004 | 436,189 |
| Marketable securities available-for-sale | 617,951 | 592,023 | 422,391 | 109,761 |
| Accounts receivables, net of allowance for doubtful accounts of $12,313 at December 31, 2024 and December 31, 2023, respectively | 45,281 | 40,607 | 145,130 | — |
| Trade Accounts Receivable | — | — | — | 116,216,000 |
| Other receivables | 1,625 | 3,926 | 2,385 | 15,600 |
| Inventories | 70,054 | 53,290 | 59,446 | 61,335 |
| Prepaid manufacturing | — | — | 0 | 159,655,000 |
| Prepaid expenses and other current assets | 18,147 | 18,995 | 85,629 | 73,764 |
| Total current assets | 848,941 | 859,120 | 916,985 | 972,520 |
| Property and equipment, net | 39,001 | 37,297 | 37,596 | 35,020 |
| Operating lease right-of-use assets | 21,608 | 24,287 | 25,745 | 25,964 |
| Goodwill | 1,946 | 2,067 | 2,006 | 2,125 |
| Restricted cash | — | — | 207,000 | 219,000 |
| Other assets (Note 9) | 74,760 | 74,325 | 3,311 | 3,398 |
| Total assets | 986,256 | 997,096 | 985,850 | 1,039,246 |
| Liabilities and stockholders’ equity | ||||
| Current liabilities: | ||||
| Accounts payable | 9,061 | 5,245 | 3,211 | 2,600 |
| Accrued research and development | 4,310 | 2,982 | 4,775 | 4,688 |
| CEPI accrual (Note 9) | — | 0 | 107,738,000 | 128,848,000 |
| Accrued liabilities (Note 7) | 61,066 | 49,448 | 30,719 | 49,796 |
| Warrant liability | — | — | 0 | 18,016,000 |
| Deferred revenue | — | — | 0 | 349,864,000 |
| Other current liabilities | 4,197 | 4,520 | 3,631 | 2,590 |
| Total current liabilities | 78,634 | 62,195 | 150,074 | 556,402 |
| Long-term debt, net of debt discounts of $1,094 and $1,394 at December 31, 2020 and 2019, respectively | — | — | — | 0 |
| Convertible Notes, net of debt discount of $1,646 and $2,802 at December 31, 2024 and December 31, 2023, respectively (Note 10) | 223,854 | 222,698 | 221,578 | 220,490 |
| Long-term portion of lease liabilities | 26,388 | 29,720 | 32,801 | 34,316 |
| CEPI accrual long-term (Note 9) | 60,337 | 60,337 | — | — |
| Other long-term liabilities | 244 | 74 | 384 | 5,664 |
| Total liabilities | 389,457 | 375,024 | 404,837 | 816,872 |
| Stockholders’ equity: | ||||
| Preferred stock: $0.001 par value, 5,000 shares authorized at December 31, 2024, and 2023; zero shares outstanding at December 31, 2024 and 2023 | 0 | 0 | 0 | — |
| Common stock: $0.001 par value; 278,000 shares authorized at December 31, 2024 and 2023; 125,450 shares and 129,530 shares issued and outstanding at December 31, 2024 and 2023, respectively | 125 | 130 | 128 | 123 |
| Additional paid-in capital | 1,504,671 | 1,554,634 | 1,510,518 | 1,441,868 |
| Accumulated other comprehensive loss | (4,722) | (2,108) | (5,438) | (2,266) |
| Accumulated deficit | (903,275) | (930,584) | (924,195) | (1,217,351) |
| Total stockholders’ equity | 596,799 | 622,072 | 581,013 | 222,374 |
| Total liabilities and stockholders’ equity | 986,256 | 997,096 | 985,850 | 1,039,246 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.